Ratings by Daiwa Securities (Narumi Nakagiri)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/12/2026 | Merck | MRK | Upgrade | Outperform (2) (Neutral (3)) |
130.92 (135.55) |
3.54% | Details | |
| 5/14/2026 | Illumina | ILMN | Upgrade | Outperform (2) (Neutral (3)) |
145.70 (192.64) |
32.22% | Details | |
| 4/22/2026 | Abbott Labs | ABT | Downgrade | Neutral (3) (Outperform (2)) |
96.00 (111.27) |
15.91% | Details | |
| 2/12/2026 | Pfizer | PFE | Downgrade | Neutral (3) (Outperform (2)) |
27.61 (26.80) |
-2.93% | Details | |
| 12/16/2025 | Eli Lilly | LLY | Upgrade | Buy (1) (Neutral (3)) |
1027.51 (1209.00) |
17.66% | Details | |
| 10/20/2025 | Johnson & Johnson | JNJ | Upgrade | Outperform (2) (Neutral (3)) |
192.12 (262.08) |
36.41% | Details | |
| 8/18/2025 | Eli Lilly | LLY | Downgrade | Neutral (3) (Outperform (2)) |
701.23 (1027.51) |
46.53% | Details | |
| 8/12/2025 | Illumina | ILMN | Downgrade | Neutral (3) (Outperform (2)) |
94.56 (145.70) |
54.08% | Details | |
| 8/7/2025 | Abbvie | ABBV | Upgrade | Outperform (2) (Neutral (3)) |
198.55 (250.82) |
26.33% | Details | |
| 8/5/2025 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (3) (Outperform (2)) |
44.23 (64.65) |
46.17% | Details | |
| 12/5/2024 | Abbvie | ABBV | Downgrade | Neutral (3) (Buy (1)) |
176.46 (250.82) |
42.14% | Details | |
| 11/13/2024 | Bristol-Myers Squibb Co. | BMY | Upgrade | Outperform (2) (Neutral (3)) |
59.82 (64.65) |
8.07% | Details | |
| 11/11/2024 | Merck | MRK | Downgrade | Neutral (3) (Outperform (2)) |
102.92 (135.55) |
31.7% | Details | |
| 8/16/2024 | Illumina | ILMN | Upgrade | Buy (1) (Neutral (3)) |
122.28 (192.64) |
57.54% | Details | |
| 8/7/2024 | Pfizer | PFE | Upgrade | Outperform (2) (Neutral (3)) |
29.32 (26.80) |
-8.59% | Details | |
| 7/31/2024 | Edwards Lifesciences | EW | Upgrade | Outperform (2) (Neutral (3)) |
63.74 (92.56) |
45.21% | Details | |
| 7/23/2024 | Johnson & Johnson | JNJ | Downgrade | Neutral (3) (Outperform (2)) |
154.69 (262.08) |
69.42% | Details | |
| 12/21/2023 | Amgen | AMGN | Upgrade | Buy (1) (Neutral (3)) |
278.44 (417.84) |
50.06% | Details | |
| 11/2/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (3) (Outperform (2)) |
51.53 (64.65) |
25.46% | Details | |
| 2/14/2023 | Merck | MRK | Maintain | Outperform (2) (N/A) |
|
Details | ||
| 8/12/2022 | Amgen | AMGN | Maintain | Buy (1) (N/A) |
|
Details | ||
| 7/6/2022 | Merck | MRK | Upgrade | Outperform (2) (Sell (5)) |
92.64 (135.55) |
46.32% | Details | |
| 5/6/2022 | Abbvie | ABBV | Downgrade | Sell (5) (Buy (1)) |
151.59 (250.82) |
65.46% | Details | |
| 12/16/2021 | Merck | MRK | New Coverage | Neutral (3) (N/A) |
73.72 (135.55) |
83.87% | Details | |
| 9/23/2021 | Amgen | AMGN | Downgrade | Neutral (3) (Outperform (2)) |
213.64 (417.84) |
95.58% | Details | |
| 8/5/2021 | Amgen | AMGN | Downgrade | Outperform (2) (Buy (1)) |
228.31 (417.84) |
83.01% | Details |
